Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10323661" target="_blank" >RIV/00064203:_____/16:10323661 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/16:10323661

Výsledek na webu

<a href="http://dx.doi.org/10.1080/2162402X.2015.1088631" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1088631</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2015.1088631" target="_blank" >10.1080/2162402X.2015.1088631</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Popis výsledku v původním jazyce

Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

Název v anglickém jazyce

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Popis výsledku anglicky

Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OncoImmunology [online]

ISSN

2162-402X

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000373385700019

EID výsledku v databázi Scopus

2-s2.0-84961671432